In Brief: Janssen Rivizor
Executive Summary
Janssen Rivizor: Oncologic Drugs Advisory Committee will discuss Janssen's vorozole NDA (20-817) for treatment of advanced breast cancer in post-menopausal women with disease progression following anti-estrogen therapy on the morning of Sept. 18. In the afternoon, the committee will review Sanofi's Photofrin (porfimer sodium) sNDA (20-451) for two indications: reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial non small-cell lung cancer, and use against endobronchial carcinoma in situ or microinvasive NSCLC in patients for whom surgery or radiotherapy are not indicated. The advisory committee will begin at 8 a.m. at the Bethesda, Md. Holiday Inn...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth